{"id":742284,"date":"2013-11-15T17:00:00","date_gmt":"2013-11-15T17:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/"},"modified":"2023-03-22T00:04:32","modified_gmt":"2023-03-22T04:04:32","slug":"interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","title":{"rendered":"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      will present additional data from patients with advanced melanoma from<br \/>\n      the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th<br \/>\n      International Congress of the Society for Melanoma Research in<br \/>\n      Philadelphia. MK-3475 is Merck\u2019s investigational anti-PD-1<br \/>\n      immunotherapy. The additional data are from PN001, an ongoing<br \/>\n      multi-center, single-arm open-label study evaluating MK-3475 monotherapy<br \/>\n      in more than 1,000 patients with diverse late-stage cancers (metastatic<br \/>\n      carcinoma), predominantly lung and melanoma. The data to be presented<br \/>\n      are for patients in the melanoma cohort.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50752404&#038;newsitemid=20131115005915&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=0796a92d63ae341e075c4890afb07104\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50752404&#038;newsitemid=20131115005915&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=88a5acc6a4f7cb30c4a48e575832c5d4\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50752404&#038;newsitemid=20131115005915&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=f1954419cba944c8c07cf74728784272\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50752404&#038;newsitemid=20131115005915&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=41e47199114acba873123caf33c4ed1d\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50752404&#038;newsitemid=20131115005915&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=848459c65f69456d74f992dcb0fbd49b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131115005915r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Merck\u2019s investigational anti-PD-1 immunotherapy. The additional data are from PN001, an ongoing multi-center, single-arm open-label study evaluating MK-3475 monotherapy in more than 1,000 patients with diverse late-stage cancers (metastatic carcinoma), predominantly lung and melanoma. The data to be presented are for patients in the melanoma cohort. About Merck Today&#8217;s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742284","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Merck\u2019s investigational anti-PD-1 immunotherapy. The additional data are from PN001, an ongoing multi-center, single-arm open-label study evaluating MK-3475 monotherapy in more than 1,000 patients with diverse late-stage cancers (metastatic carcinoma), predominantly lung and melanoma. The data to be presented are for patients in the melanoma cohort. About Merck Today&#039;s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\",\"name\":\"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-11-15T17:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Merck\u2019s investigational anti-PD-1 immunotherapy. The additional data are from PN001, an ongoing multi-center, single-arm open-label study evaluating MK-3475 monotherapy in more than 1,000 patients with diverse late-stage cancers (metastatic carcinoma), predominantly lung and melanoma. The data to be presented are for patients in the melanoma cohort. About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:32+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","name":"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx","datePublished":"2013-11-15T17:00:00+00:00","dateModified":"2023-03-22T04:04:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131115005915r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/interim-data-to-be-presented-for-mk-3475-mercks-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Interim Data to Be Presented for MK-3475, Merck\u2019s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c828fff4-5819-4061-a22e-aaa1b86856aa","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742284\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742284"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}